Xenon Pharmaceuticals Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for neurological disorders, including epilepsy and major depressive disorder, with its lead program azetukalner (a Kv7 potassium channel opener) in late-stage clinical trials.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| KENNEY CHRISTOPHER JOHNChief Medical Officer | Sell | $383K | 6,368at $60.17 | Aug 28, 2026 |
| KENNEY CHRISTOPHER JOHNChief Medical Officer | Sell | $43K | 700at $60.98 | Aug 28, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable XENE activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.